ICM
LDOS icon

Invenomic Capital Management’s Leidos LDOS Stock Holding History

Invenomic Capital Management’s Portfolio LDOS Stock Details LDOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,085
Closed -$4.59M – 164
2025
Q2 		$4.59M Sell
29,085
-4,748
-14% -$702K 0.26% 102
2025
Q1 		$4.57M Buy
+33,833
New +$4.72M 0.23% 118

Other funds holding LDOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Invenomic Capital Management's LDOS Position: Q3 2025 in Review

Invenomic Capital Management sold out of Leidos (LDOS) in Q3 2025, closing a stake of 29,085 shares — an estimated $4.59M sold.

Invenomic Capital Management first reported a position in LDOS in Q1 2025 and held it in 2 quarters. The position peaked at $4.59M in Q2 2025. 902 funds tracked by Wall St. Rank hold LDOS as of Q3 2025.

  • Invenomic Capital Management reported no remaining Leidos position as of Q3 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 29,085 Leidos shares in Q3 2025, an estimated $4.59M.
  • Invenomic Capital Management first reported a position in Leidos in Q1 2025 and held it in 2 quarters.
  • Invenomic Capital Management's Leidos position peaked at $4.59M in Q2 2025.
  • 902 funds tracked by Wall St. Rank held Leidos as of Q3 2025.

Based on Invenomic Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.